Monoclonal antibodies: the stars of therapeutic proteins
Hybridoma technology for the production of monoclonal antibodies (mAbs), awarded the Nobel Prize for Medicine in 1984, revolutionized serotherapy, which previously used patient serum containing mixtures of antibodies. More targeted and therefore more effective, mAbs offer innovative perspectives in the treatment of various diseases, and have become an essential therapeutic strategy in our pharmaceutical arsenal.
